Parade on MSN1h
Ozempic Could Get Way Too Expensive Under Trump—Here's What You Can Do
President Trump’s proposed tariffs on Denmark could have costly consequences for Americans relying on GLP-1 medications like Ozempic and Wegovy—and consumers are becoming increasingly concerned. While ...
Weight loss drug opportunity is increasingly coming into focus for Indian pharma
Weight loss drugs, which took the US market by storm, are looking to be a big opportunity for drug makers in India. Several ...
Novo Nordisk's Innovation Supports a Wide Moat and GLP-1 Market Growth
We expect Novo to gain $75 billion of a more than $200 billion global GLP-1 market in diabetes and obesity by 2031, ahead of semaglutide's 2032 patent expiration, with Lilly standing as the firm's key ...